Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China
- Conditions
- Rectal Cancer
- Registration Number
- NCT05108753
- Lead Sponsor
- Shanghai Minimally Invasive Surgery Center
- Brief Summary
Transanal total mesorectal excision (TaTME) is an alternative for mid-low rectal cancer. In China, this procedure has been performed in high-volume centers with structured training curriculums. This study aimed to evaluate the short-term outcomes during the initial implementation of the TaTME procedure in high-volume centers who followed structured training curriculums in China.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 175
- Age between 18 and 75 years
- American Society of Anesthesiologists (ASA) score I to III
- A biopsy proven histological diagnosis of rectal carcinoma
- Undergoing transanal total mesorectal excision
- Pregnant or lactating women
- Synchronous rectal carcinoma
- History of colorectal cancer or other malignant tumors
- Clinical evidence of metastasis
- Emergency procedure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of anastomotic leakage thirty days after surgery according to the International Rectal Cancer Study Group
- Secondary Outcome Measures
Name Time Method incidence of positivecircumferential resection margin 30 days after surgery The positive circumferential resection margin (CRM) was defined as the presence of tumor cells within 1 mm from the CRM
incidence of Defecation disorders 6 months after surgery A Wexner score \>10 indicated the existence of defecation dysfunction
incidence of positive distal resection margin 30 days after surgery A positive distal resection margin (DRM) was diagnosed with the presence of tumor cells within 1mm from the DRM
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Ruijin Hospital
🇨🇳Shanghai, Shanghai, China
Shanghai Minimally Invasive Surgery Center
🇨🇳Shanghai, China
Ruijin Hospital🇨🇳Shanghai, Shanghai, China